How to buy ARCA biopharma stock | $4.21

ARCA biopharma, Inc is a biotechnology business based in the US. ARCA biopharma shares (ABIO) are listed on the NASDAQ and all prices are listed in US Dollars. ARCA biopharma employs 13 staff and has a market cap (total outstanding shares value) of USD$39.6 million.

How to buy shares in ARCA biopharma

1. Compare share trading platforms. If you're a beginner, look for a platform with low commissions, expert ratings and investment tools to track your portfolio. Narrow down top brands with our comparison table.
2. Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and bank information. Fund your account with a bank transfer, credit card or debit card.
3. Search for ARCA biopharma. Find the stock by name or ticker symbol: ABIO. Research its history to confirm it's a solid investment against your financial goals.
4. Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until ARCA biopharma reaches your desired price. To spread out your purchase, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
5. Decide on how many to buy. At last close price of USD$4.21, weigh your budget against a diversified portfolio that can minimize risk through the market's ups and downs. You may be able to buy a fractional share of ARCA biopharma, depending on your broker.
6. Check in on your investment. Congratulations, you own a part of ARCA biopharma. Optimize your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.

ARCA biopharma share price

Use our graph to track the performance of ABIO stocks over time.

ARCA biopharma shares at a glance

• Key figures

Information last updated 2020-12-27.

Latest market close	USD$4.21
52-week range	USD$2.21 - USD$10.25
50-day moving average	USD$4.1185
200-day moving average	USD$5.2672
Wall St. target price	USD$7
PE ratio	N/A
Dividend yield	N/A (0%)
Earnings per share (TTM)	USD$-6.667

Buy ARCA biopharma shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.

Is it a good time to buy ARCA biopharma stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

Technical Analysis of ARCA biopharma, Inc by TradingView

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

ARCA biopharma price performance over time

Historical closes compared with the close of $4.21 from 2020-10-19

1 week (2021-01-14)	-6.03%
1 month (2020-12-21)	-1.41%
3 months (2020-10-21)	3.19%
6 months (2020-07-21)	-44.31%

1 year (2020-01-21)	-28.16%
2 years (2019-01-18)	891.05%
3 years (2018-01-19)	163.13%
5 years (2016-01-21)	6.05%

ARCA biopharma financials

Gross profit TTM	USD$0
Return on assets TTM	-11.94%
Return on equity TTM	-19.71%
Profit margin	0%
Book value	$5.434
Market capitalisation	USD$39.6 million

TTM: trailing 12 months

Shorting ARCA biopharma shares

There are currently 41,092 ARCA biopharma shares held short by investors – that's known as ARCA biopharma's "short interest". This figure is 17.5% down from 49,824 last month.

There are a few different ways that this level of interest in shorting ARCA biopharma shares can be evaluated.

ARCA biopharma's "short interest ratio" (SIR)

ARCA biopharma's "short interest ratio" (SIR) is the quantity of ARCA biopharma shares currently shorted divided by the average quantity of ARCA biopharma shares traded daily (recently around 410920). ARCA biopharma's SIR currently stands at 0.1. In other words for every 100,000 ARCA biopharma shares traded daily on the market, roughly 100 shares are currently held short.

However ARCA biopharma's short interest can also be evaluated against the total number of ARCA biopharma shares, or, against the total number of tradable ARCA biopharma shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case ARCA biopharma's short interest could be expressed as 0% of the outstanding shares (for every 100,000 ARCA biopharma shares in existence, roughly 0 shares are currently held short) or 0.0044% of the tradable shares (for every 100,000 tradable ARCA biopharma shares, roughly 4 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against ARCA biopharma.

Find out more about how you can short ARCA biopharma stock.

ARCA biopharma share dividends

We're not expecting ARCA biopharma to pay a dividend over the next 12 months.

Have ARCA biopharma's shares ever split?

ARCA biopharma's shares were split on a 1:18 basis on 4 April 2019. So if you had owned 18 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your ARCA biopharma shares – just the quantity. However, indirectly, the new 1700% higher share price could have impacted the market appetite for ARCA biopharma shares which in turn could have impacted ARCA biopharma's share price.

ARCA biopharma share price volatility

Over the last 12 months, ARCA biopharma's shares have ranged in value from as little as $2.21 up to $10.25. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while ARCA biopharma's is 2.8588. This would suggest that ARCA biopharma's shares are significantly more volatile than the average for this exchange and represent a higher risk.

ARCA biopharma overview

ARCA biopharma, Inc. operates as a biopharmaceutical company applying a precision medicine approach to developing and commercializing genetically targeted therapies for cardiovascular diseases. Its lead product candidate, Gencaro (bucindolol hydrochloride) is pharmacogenetically-targeted beta-adrenergic receptor antagonist, which is in the development for the treatment of atrial fibrillation in certain patients who also have heart failure (HF). The company also engages in the development of AB171, a thiol-substituted isosorbide mononitrate for the treatment of HF and peripheral arterial disease. ARCA biopharma, Inc. is headquartered in Westminster, Colorado.

Frequently asked questions

• What percentage of ARCA biopharma is owned by insiders or institutions?

  Currently 0.398% of ARCA biopharma shares are held by insiders and 8.458% by institutions.

• How many people work for ARCA biopharma?

  Latest data suggests 13 work at ARCA biopharma.

• When does the fiscal year end for ARCA biopharma?

  ARCA biopharma's fiscal year ends in December.

• Where is ARCA biopharma based?

  ARCA biopharma's address is: 10170 Church Ranch Way, Westminster, CO, United States, 80021

• What is ARCA biopharma's ISIN number?

  ARCA biopharma's international securities identification number is: US00211Y5069

• What is ARCA biopharma's CUSIP number?

  ARCA biopharma's Committee on Uniform Securities Identification Procedures number is: 00211Y100